Genomic and transcriptomic analysis of GBM patients treated with anti-PD-1 antibodies revealed a significant enrichment of the immunosuppressive transcriptomic signature in non-responders, along with differences in T cell clonal diversity and tumor microenvironment profiles (12). This evidence concerns the gene PDCD1 and glioblastoma.